Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Pharma Gmbh & Co Kg

Udo Maier

Matthias Grauert

Steffen Breitfelder

Trixi Brandl

Christoph Hoenke

Matthias Hoffmann

Stefan Scheuerer

Alexander Pautsch

Anne T Joergensen

Michael Paul Pieper

Ingo Pragst

Klaus Erb

Martin Steegmaier

Darryl McConnell

Steffen Steurer

Andreas Schoop

Frank Hilberg

Dirk Kessler

Bodo Betzemeier

Ulrike Weyer-Czernilofsky

Maria Impagnatiello

Irene Waizenegger

Bernd Krist

Thomas Gerstberger

Christian Klein

Ralph Brueckner

Michael Gmachl

Andreas Zoephel

Oliver Simon

Norbert Schweifer

Charlotte Reither

Riccardo Giovannini

Stefan Peters

Gerhard Schaenzle

Sara Frattini

Enzo Cereda

Frank Buettner

Eckhart Bauer

Matthias Hoffman

Monica Quai

Gerhard Schaenze

Frank Kalkbrenner

Anne Joergensen

Frank Büttner

New compounds of Formula (1) are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney. 

Pteridinone derivatives as PI3-kinases inhibitors

The present invention relates to compounds of general formula (I), wherein the groups A, R, R, Rand Rhave the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-quinazolines and the use thereof as pharmaceutical compositions.

Thiazolyl-dihydro-quinazolines

Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups Rto Rhave the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.

Thiazolyl-dihydro-quinazoline compounds and processes for preparing same

New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.

Inhibitors of PI3-kinases

The present invention encompasses compounds of the general formula (1) in which

Thiazolyl-dihydro-indazoles

Thiazolyl-dihydro-indazole

Thiazolyl-dihydro-quinazoline

Disclosed are compounds of general formula (I), wherein the groups R, R, Rand Rhave the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts, solvates and hydrates thereof, and processes for preparing these thiazolyl-dihydro-cyclopentapyrazoles and the use thereof as pharmaceutical compositions.

Thiazolyl-dihydro-cyclopentapyrazole

Growing community of inventors

Senden, Germany

Udo Maier